Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100
Authors:
- Christopher KollmannCKChristopher Kollmann
- Françoise GiguelFGFrançoise Giguel
- Ting-Chao ChouTCTing-Chao Chou
- Martin S. HirschMHMartin S. Hirsch
- 1 October 2000
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 25 (2) , 99-102
Abstract
Attachment and entry of HIV-1 into CD4 cells involve a series of events in which different viral envelope proteins interact with specific cell receptors, culminating in fusion of viral and cell membranes. AMD-3100 is a small molecule inhibitor of HIV-1 attachment to the CXCR4 chemokine receptor, and T-20 is a synthetic peptide corresponding to a region of HIV-1 gp41 that blocks fusion to cell membranes. To evaluate the interaction between agents acting at two different steps of the entry process, we conducted in vitro studies of the combination of T-20 and AMD-3100 against an X4 HIV-1 isolate. Single drugs or multiply diluted fixed ratio combinations of drugs were added to peripheral blood mononuclear cells infected with a clinical isolate, 14aPre. Drug interactions were evaluated using the median-effect principle and the combination index technique. The 50% inhibitory concentration (IC50) for T-20 was 0.10 μg/ml and for AMD-3100 was 0.19 μg/ml. Synergy was observed between T-20 and AMD-3100 and this increased with higher inhibitory concentrations, with combination indices ranging from 0.62 at IC50 to 0.02 at IC95. Whether these synergistic interactions translate into clinical benefit will need to be addressed in the context of clinical trials. Address correspondence and reprint requests to Martin S. Hirsch, Infectious Diseases Unit, Gray 5, Massachusetts General Hospital, Fruit Street, Boston, MA 02114, U.S.A.; e-mail: [email protected] This work was presented in part at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, U.S.A., 2000 [abstract #500]. Manuscript received May 12, 2000; accepted July 18, 2000. © 2000 Lippincott Williams & Wilkins, Inc.Keywords
This publication has 11 references indexed in Scilit:
- Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human VolunteersAntimicrobial Agents and Chemotherapy, 2000
- Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individualAIDS, 1999
- Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral TherapyNew England Journal of Medicine, 1999
- Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapyNature Medicine, 1999
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entryNature Medicine, 1998
- The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and ImmunogensScience, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory PeptidesJournal of Virology, 1998
- AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptorNature Medicine, 1998
- Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4Journal of Experimental Medicine, 1997